Vesalio Appoints Daniel Davis to Its Board of Directors and as Advisor to the CEO
Proven medical device executive brings experience building thrombectomy businesses and guiding product strategy to support Vesalio's continued growth
DALLAS, Oct. 15, 2026 /PRNewswire/ -- Vesalio, a global leader in vascular intervention, announces the appointment of Daniel Davis to its Board of Directors and as Advisor to the CEO. Davis brings more than 25 years of experience building medical device businesses, shaping product strategy, and scaling commercial organizations, including senior leadership roles at Penumbra and Imperative Care.
In his new roles with Vesalio, Davis will provide strategic guidance on product portfolio priorities and commercial growth as the company focuses on the recently published NATURE coronary thrombectomy clinical data and expands its commercial footprint across coronary, peripheral vascular, and neurovascular markets. His experience spans early-stage businesses through public-company leadership, bringing a board-level and an operator's perspective to the opportunities and organizational demands of expansion.
"Daniel brings a proven record of building businesses from the early stage through initial public offering, shaping the product and commercial strategies that turn early clinical experience into market leadership," said Steve Rybka, Chief Executive Officer of Vesalio. "He joins us at a moment of significant momentum given the positive results from the NATURE randomized controlled trial (RCT) involving our enVast coronary thrombectomy technology. His perspective will prove especially valuable throughout this next phase of transformative growth. Daniel's experience will help us focus on Vesalio's highest-impact opportunities, accelerate execution, and scale the organization. We are pleased to welcome him as a board member and advisor."
At Imperative Care, Davis held leadership roles including President, Chief Operating Officer, and Chief Strategy Officer, taking the company from early launch to market leadership in stroke and later building vascular thrombectomy and the Telos robotic-enabled remote stroke businesses. Previously, he served as President and Chief Commercial Officer at Penumbra. After joining Penumbra as a startup in 2007, he led its growth from an early-stage business through its IPO, responsible for driving strategy and commercial leadership across all neurovascular, coronary, and peripheral vascular technologies.
"Vesalio is tackling critical unmet clinical needs across coronary, neurovascular, and peripheral thrombectomy," said Davis. "The recently published NATURE RCT marks a pivotal moment for the company and a catalyst for its next phase of growth. I look forward to working with Steve and the board to turn that momentum into clear priorities and decisive execution. Working closely with physicians, we will refine our thrombectomy platforms and streamline procedural workflows—with a clear goal: advancing care for patients with significant clot burden."
About Vesalio
Vesalio is a privately held medical device company focused on advancing care for patients with thromboembolic vascular disease. Our proprietary technologies are designed to enable physicians to effectively remove all clot types and restore critical blood flow to ischemic tissue in the heart, brain, and peripheral vasculature.
Vesalio products have been used to treat more than 20,000 patients in more than 60 countries. For more information, visit www.vesalio.com.
Investor Contacts
Steve Rybka, CEO, Vesalio
J.D. McCulloch, CFO, Vesalio
SOURCE Vesalio
Share this article